Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07591571 | To Evaluate the Preliminary Efficacy of Our Digitally Enhanced CHW-led Intervention in Newly Diagnosed PDAC | recruiting | N/A | 60 | Loma Linda UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04789486 | Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06320990 | Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection(MCN_Tam) | recruiting | Phase 1 | 15 | University of NebraskaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | recruiting | Phase 1 / Phase 2 | 183 | Tango Therapeutics, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07557225 | 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors | recruiting | N/A | 200 | Peking University First HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07586813 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors(N01-A-PICIT-GI) | recruiting | Phase 2 | 220 | Peking University People's HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07532590 | Patients With Pancreatic Tumor: Use of an App to Monitor Progress in a Simple and Intuitive Way by Periodically Completing Targeted Questionnaires and Providing Educational and Informational Content (PancreasPlus). | recruiting | N/A | 185 | Casa di Cura Dott. PederzoliOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07436312 | Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer(U-TRANS) | recruiting | N/A | 170 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07554560 | Nutrition Intervention for Pancreatic Cancer | recruiting | N/A | 18 | Children's Hospital of PhiladelphiaOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT01102569 | Pancreatic Cancer Genetics | recruiting | — | 100 | Columbia UniversityOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT04881487 | Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy(ARCADE) | recruiting | N/A | 174 | UMC UtrechtOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05914987 | Determining Individualized Cancer Therapy in Pancreatic Cancer(PREDICT-PANC) | recruiting | — | 1,000 | Medical College of WisconsinOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06228599 | Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence(PROTECT-PANC) | recruiting | N/A | 40 | Medical College of WisconsinOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06941857 | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer | recruiting | Phase 2 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07354919 | Axelopran for Advanced Cancer in Patients Receiving Opioids(AxeCan) | recruiting | Phase 2 | 34 | HealthPartners InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05296421 | Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer | recruiting | N/A | 16 | Rutgers, The State University of New JerseyOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07549958 | PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC) | recruiting | Phase 1 | 18 | University of California, IrvineOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07563738 | A 2-part Phase 1/2 Open-label Trial on ODM-212(TEADCO) | recruiting | Phase 1 / Phase 2 | 229 | Orion Corporation, Orion PharmaINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT02838836 | Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers | recruiting | — | 620 | University of Missouri-ColumbiaOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06050317 | Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer | recruiting | Phase 2 | 25 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07560540 | Nutritional Intervention Implication in Enhanced Recovery After Surgery for Whipple Procedure({ERAS}) | recruiting | N/A | 20 | University of Veterinary and Animal Sciences, Lahore - PakistanOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06648434 | MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 | 51 | Washington University School of MedicineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07478523 | FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers(FAPDIG) | recruiting | Phase 2 | 120 | University Hospital, BordeauxOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05428358 | Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery(MAGIPAC) | recruiting | N/A | 200 | University of AarhusOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07206355 | In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary Cancers(Map HPB) | recruiting | — | 160 | University of NottinghamOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04011982 | PATAKESS Protocol : Clinical and Biological Analysis of Exocrine Pancreatic Tumors(PATAKESS) | recruiting | — | 300 | Centre Leon BerardOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06844422 | Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND) | recruiting | Phase 1 / Phase 2 | 37 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06549725 | Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening | recruiting | N/A | 419 | Lipidica, a.s.INDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06723236 | A Study of MGC028 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 124 | MacroGenicsINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07408505 | Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer | recruiting | N/A | 56 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07552467 | Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors | recruiting | — | 26 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04951804 | EUS-CPN With and Without Bupivacaine(EUS-NB) | recruiting | N/A | 180 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05006131 | Pancreatic Cancer Screening for At-risk Individuals(PancreasScan) | recruiting | — | 1,395 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06483555 | Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel(PANGEA) | recruiting | Phase 1 / Phase 2 | 104 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT06330441 | Pancreatic Cancer Screening in a Population at High Risk(ScrePan) | recruiting | N/A | 700 | Masaryk Memorial Cancer InstituteOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07542002 | Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors:A Prospective Exploratory Study | recruiting | Phase 2 | 37 | Ningbo Medical Center Lihuili HospitalOTHER_GOV | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06705335 | Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma(CONVERCAP) | recruiting | — | 50 | Institut BergoniéOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07536087 | Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors | recruiting | N/A | 50 | Institute for Clinical and Experimental MedicineOTHER_GOV | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06453486 | A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment(ABLATE) | recruiting | Phase 2 | 43 | University Health Network, TorontoOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05065801 | Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients(GABRINOX2) | recruiting | Phase 2 | 162 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06659705 | Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)(INDIGO-FAPI) | recruiting | Phase 2 | 35 | Institut CurieOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06799637 | Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments | recruiting | Phase 1 / Phase 2 | 350 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07126158 | Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma | recruiting | Phase 2 | 36 | Washington University School of MedicineOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07353645 | KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 49 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 15, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2026source: clinicaltrials